Record-Breaking Revenue and Growth
ChromaDex delivered record revenues of $29.1 million for Q4 2024, a 37% increase year-over-year, and net income of $7.2 million. Full year net revenues were $99.6 million, a 19% growth YOY.
Strong Cash Flow and Financial Position
Generated $12.1 million in positive cash flow from operations in 2024, ended the year with $44.7 million in cash and no debt.
E-commerce and Ingredient Business Growth
E-commerce channel net sales were $17.3 million, a 30% increase YOY. Food grade and pharmaceutical-grade Niagen ingredient business had net sales of $5.3 million, a 96% increase YOY.
Improved Operational Efficiency
Gross margins improved by 150 basis points to 62.5% in Q4 2024, reflecting operational efficiency and a strategic business mix.
Reduction in Expenses
Selling and marketing expenses as a percentage of net sales improved by 90 basis points, and general and administrative expenses decreased by $6.6 million YOY.
Strategic Initiatives and Name Change
ChromaDex plans to announce a company name change to better represent its strategic direction and growth.